New Migraine Prevention Guidelines
Major medical societies release updated migraine prevention guidelines highlighting newer targeted therapies.
Anonymous
Key Points
1
The guidelines are endorsed by the American Academy of Family Physicians (AAFP).
2
CGRP-targeted migraine preventives have a defined approval timeline: erenumab (Aimovig) approved in 2018, followed by fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti); oral CGRP blockers rimegepant (Nurtec) and atogepant (Qulipta) were approved for prevention in 2021.
3
The CGRP-class drugs can substantially reduce migraine days for some patients, with reported reductions reaching up to about 70%.
4
The guidelines note that roughly 8 million adults in the United States are eligible for preventive migraine treatment.
5
A multidisciplinary guideline panel, convened in January 2018, included patient representatives and advocates alongside methodologists and content experts to develop the recommendations.
The American Academy of Neurology and American Headache Society released their first migraine prevention guidelines in 12 years, based on a review of 217 studies through June 2024. Neurology Live The new guidance emphasizes newer CGRP-targeted drugs like Aimovig and Ajovy alongside older treatments like beta-blockers and Botox. The guidelines recommend preventive treatment for adults with four or more migraine days per month or whose migraines disrupt work and daily life.
About 8 million U.S. adults qualify for preventive migraine treatment under the new criteria. Medical Xpress CGRP-targeted therapies—a newer class approved since 2018—can reduce migraine days by up to 70 percent for some patients. Pain News Network The guidelines reflect a major shift toward proactive prevention with modern drugs while keeping older options available for patients who prefer them.
Who Qualifies for Migraine Prevention
The updated guidelines set clear eligibility rules. Adults should start preventive treatment if they have four or more migraine days per month. MedPage Today They also qualify if migraines cause four or more moderate-to-severe headache days monthly or significantly impair work or daily tasks. Chronic migraine—defined as 15 or more headache days per month for at least three months, with eight days showing migraine features—also qualifies for prevention.
CGRP Drugs Show the Strongest Evidence
CGRP-targeted therapies topped the guidelines' evidence rankings for both episodic and chronic migraine. Pain News Network These include injectable monoclonal antibodies: erenumab (Aimovig, approved 2018), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti). MedPage Today Oral CGRP blockers rimegepant (Nurtec) and atogepant (Qulipta) gained prevention approval in 2021. Clinical trials showed these drugs reduce migraine days by up to 70 percent in some patients.
CGRP drugs work differently from older preventives. Mirage News They target a specific pain pathway in the brain. Doctors can give them as monthly or quarterly injections or daily oral pills. The guidelines note that CGRP therapies represent a major advance, though older drugs remain effective for many patients.
Older Preventive Drugs Still Have a Role
Beta-blockers like propranolol and metoprolol remain standard options. Antiseizure medications topiramate and valproate also prevent migraines in many adults. Medical Xpress Botox (onabotulinumtoxinA) injections work for chronic migraine. The guidelines recommend tailoring drug choice to each patient's needs, medical history, and preferences rather than forcing everyone onto newer drugs.
Expert Panel Shaped Guidelines With Patient Input
A multidisciplinary panel convened in January 2018 to develop the recommendations. Mirage News The team included neurologists, methodologists, patient advocates, and other experts. The American Academy of Family Physicians also endorsed the guidelines. This diverse input ensured the guidance reflects both clinical evidence and real-world patient experiences and priorities.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
11
Articles
2
Reach
13
A
AnonymousAuthor
